Research Paper Volume 13, Issue 9 pp 12514—12525

Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells

Capsanthin has synthetic effects when combined with Tarceva in monotherapy and in two-drug combinations in MDA-MB-231 and MDA-MB-231-Tarecva resistant cells. (A) MDA-MB-231 cell was treated with capsanthin(10 μM) and Tarceva(5 μM) in monotherapy and in two-drug combinations for 72 hours. *P **P ***P B) MDA-MB-231-TR cell was treated with capsanthin (0, 2.5, 5, 10, 20, and 40 μM) and Tarceva(100 μM) in monotherapy and in two-drug combinations for 48 and 72 hours. *P **P ***P

Figure 4. Capsanthin has synthetic effects when combined with Tarceva in monotherapy and in two-drug combinations in MDA-MB-231 and MDA-MB-231-Tarecva resistant cells. (A) MDA-MB-231 cell was treated with capsanthin(10 μM) and Tarceva(5 μM) in monotherapy and in two-drug combinations for 72 hours. *P < 0.05, **P < 0.01, ***P < 0.001. (B) MDA-MB-231-TR cell was treated with capsanthin (0, 2.5, 5, 10, 20, and 40 μM) and Tarceva(100 μM) in monotherapy and in two-drug combinations for 48 and 72 hours. *P < 0.05, **P < 0.01, ***P < 0.001.